The significance of information posted on the U.S. food and Drug Administration's website

Journal of Managed Care Pharmacy

Volumn 19, Issue 1, 2013, Pages 72-73

  Cook, G Elliott ^a   Madden, Michael M ^b  

^a Provider Resources Inc   (United States)

^b LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPARATIVE EFFECTIVENESS; DRUG APPROVAL; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; INFORMATION CENTER; INFORMATION SERVICE; LETTER; PHARMACIST; PHARMACY BENEFIT MANAGER; PUBLICATION; UNITED STATES;

EID: 84874806763     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2013.19.1.72     Document Type: Letter

References (15)

1. Marchand HC, Rose BJ, Fine AM, Kremzner ME. The U.S. Food and Drug Administration: drug information resource for formulary recommendations. J Manag Care Pharm. 2012;18(9):713-18. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=15875. Accessed January 7, 2013.
2. Navarro RP. Rediscovering FDA websites. J Manag Care Pharm. 2012;18(9):719-20. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=15876. Accessed January 7, 2013.
3. Moher D, Tsertsvadze A. Systematic reviews: when is an update an update? Lancet. 2006;367(9514):881-83.
4. Ohmer J, Miller JW, Sasich LD. Accessing FDA approval packages and briefing documents. Ann Pharmacother. 2007;41(12):2071-72.
5. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-60.
6. Turner EH, Knoepflmacher D, Shapley L. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. PLoS Med. 2012;9(3):e1001189.
7. Lee K, Bacchetti P, Sim I. Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med. 2008;5(9):e191.
8. Cook GE, Sasich LD, Sukkari SR. FDA drug information that never reaches clinicians. N Engl J Med. 2010;362(6):561-63.
9. U.S. Food and Drug Administration. Drugs@FDA. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda. Accessed January 3, 2013.
10. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21(6):597-605.
11. Schwartz LM, Woloshin S. Lost in transmission-FDA drug information that never reaches clinicians. N Engl J Med. 2009;361(18):1717-20.
12. Schwartz LM, Woloshin S. How the FDA forgot the evidence: the case of donepezil 23 mg. BMJ. 2012;344:e1086.
13. Higgins J, Green S Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration. Updated March 2011. Available at: http://handbook.cochrane.org/. Accessed January 3, 2013.
14. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(12)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. April 2012. Available at: http://effectivehealthcare.ahrq.gov/index. cfm/search-for-guides-reviews-and-reports/?productid=318&pageaction=dis playproduct. Accessed January 3, 2013.
15. FMCP Format Executive Committee. The AMCP format for formulary submissions version 3.0. J Manag Care Pharm. 2010;16(1 Suppl A):1-30. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=8256. Accessed January 7, 2013.